

LOOK BEYOND LIMITS



At Roche, we strive to push the boundaries of possibilities within ophthalmology

Continuous drug delivery system

Permanent refillable implant

Personalised healthcare

Harnessing the power of data, analytics, and digital to address unmet needs

Home Vision Monitor[®]

Smartphone application that enables remote monitoring of vision

Bispecific antibody

1 molecule, 2 targets: Ang-2 and VEGF-A

AI/machine learning


Development of algorithms to detect disease and provide novel insights for disease management

**Supporting industry partner for INSIGHT
(insight.hdrhub.org)**

Step into the future of vision with us at futureofvision.global

STEP INTO THE FUTURE

Novel MoAs and platforms targeting retinal diseases



*Led by Ionis Pharmaceuticals, Inc.

DME, diabetic macular edema; DR, diabetic retinopathy; GA, geographic atrophy; MoA, mechanism of action; nAMD, neovascular age-related macular degeneration; RVO, retinal vein occlusion

Information presented here is based on: https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.html [last accessed September 2021]; <https://www.roche.com/dam/jcr:e4cb05a5-2d53-4b58-9b7f-858a32b9d44d/en/irp20200727.pdf> [last accessed September 2021]

Please note that assets described in the pipeline have not yet received regulatory approval in any country. For any questions regarding the ophthalmology pipeline please contact: global.ophthalmology@roche.com

M-XX-00006963 | Date of Preparation October 2021